@article{KelmSeyfriedReimeretal.2017,
  author    = {Kelm, M. and Seyfried, F. and Reimer, S. and Krajinovic, K. and Miras, A. D. and Jurowich, C. and Germer, C. T. and Brand, M.},
  title     = {Proximal jejunal stoma as ultima ratio in case of traumatic distal duodenal perforation facilitating successful EndoVAC\(^{®}\) treatment: a case report},
  series = {International Journal of Surgery Case Reports},
  volume    = {41},
  journal   = {International Journal of Surgery Case Reports},
  doi       = {10.1016/j.ijscr.2017.11.022},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-159292},
  pages     = {401-403},
  year      = {2017},
  abstract  = {Introduction: During damage control surgery for blunt abdominal traumata simultaneous duodenal perforations can be missed making secondary sufficient surgical treatment challenging. Endoluminal vacuum (EndoVAC™) therapy has been shown to be a revolutionary option but has anatomical and technical limits. Presentation of the case: A 59-year old man with hemorrhagic shock due to rupture of the mesenteric root after blunt abdominal trauma received damage control treatment. Within a scheduled second-look, perforation of the posterior duodenal wall was identified. Due to local and systemic conditions, further surgical treatment was limited. Decision for endoscopic treatment was made but proved to be difficult due to the distal location. Finally, double-barreled jejunal stoma was created for transstomal EndoVAC™ treatment. Complete leakage healing was achieved and jejunostomy reversal followed subsequently. Discussion: During damage control surgery simultaneous bowel injuries can be missed leading to life-threatening complications with limited surgical options. EndoVAC™ treatment is an option for gastrointestinal perforations but has anatomical limitations that can be sufficiently shifted by a transstomal approach for intestinal leakage. Conclusion: In trauma related laparotomy complete mobilization of the duodenum is crucial. As ultima ratio, transstomal EndoVAC™ is a safe and feasible option and can be considered for similar cases.},
  language  = {en}
}
@article{AlepeeBahinskiDaneshianetal.2014,
  author    = {Alepee, Natalie and Bahinski, Anthony and Daneshian, Mardas and De Weyer, Bart and Fritsche, Ellen and Goldberg, Alan and Hansmann, Jan and Hartung, Thomas and Haycock, John and Hogberg, Helena T. and Hoelting, Lisa and Kelm, Jens M. and Kadereit, Suzanne and McVey, Emily and Landsiedel, Robert and Leist, Marcel and L{\"u}bberstedt, Marc and Noor, Fozia and Pellevoisin, Christian and Petersohn, Dirk and Pfannenbecker, Uwe and Reisinger, Kerstin and Ramirez, Tzutzuy and Rothen-Rutishauser, Barbara and Sch{\"a}fer-Korting, Monika and Zeilinger, Katrin and Zurich, Marie-Gabriele},
  title     = {State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology},
  series = {ALTEX - Alternatives to Animal Experimentation},
  volume    = {31},
  journal   = {ALTEX - Alternatives to Animal Experimentation},
  number    = {4},
  doi       = {2014; http://dx.doi.org/10.14573/altex1406111},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117826},
  pages     = {441-477},
  year      = {2014},
  abstract  = {Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs liver, lung, skin, brain are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing.},
  language  = {en}
}